Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
TG Therapeutics to Participate in the Evercore HealthCONx Conference

TGTX : 31.07 (-7.45%)
TG Therapeutics Ranked Number One on Deloitte Technology Fast 500â„¢ for Rapid Growth in Biopharmaceutical Sector

TG Therapeutics ranked first on Deloitte Technology Fast 500 due to significant growth from BRIUMVI® MS treatment revenues.Quiver AI SummaryTG Therapeutics, Inc. announced it has been ranked as the fastest-growing...

TGTX : 31.07 (-7.45%)
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500â„¢

TGTX : 31.07 (-7.45%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 31.07 (-7.45%)
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

TGTX : 31.07 (-7.45%)
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

TGTX : 31.07 (-7.45%)
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 31.07 (-7.45%)
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

AAPL : 248.05 (-2.14%)
QCOM : 153.05 (-3.08%)
AMZN : 220.52 (-4.60%)
MNKD : 5.94 (+0.17%)
SNBR : 17.87 (-5.55%)
MANH : 281.63 (-4.55%)
TGTX : 31.07 (-7.45%)
QRVO : 68.50 (-3.45%)
ZM : 82.05 (-3.01%)
WOOF : 4.14 (-6.76%)
VZ : 40.24 (-1.32%)
MCD : 290.88 (-1.76%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 0.9900 (+0.02%)
LLY : 764.71 (-1.79%)
RHHBY : 34.9100 (-2.59%)
BIIB : 146.79 (-2.56%)
TGTX : 31.07 (-7.45%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 0.9900 (+0.02%)
LLY : 764.71 (-1.79%)
RHHBY : 34.9100 (-2.59%)
BIIB : 146.79 (-2.56%)
TGTX : 31.07 (-7.45%)

Barchart Exclusives

Up 685% in 2024, Is It Too Late to Buy This Growth Stock?
After a year of electrifying returns, is AppLovin still a ticket to growth, or has the ship already sailed? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar